Yellow Fever (YF) is a mosquito-borne disease caused by the Amaril virus which has symptoms that range from mild to severe illness
and even death (est 30,000/yr). The disease, which exists in various forms, is mainly endemic to parts of Africa and Latin America
(LATAM) where 610 million are estimated to be at risk of which 219 million are living in urban settings.
Yellow fever vaccination, using a one shot live-attenuated vaccine based on 17-D is the most important measure to control YF and
has been available for decades. It is currently used in routine childhood immunization (6-9 mos) and as part of donor funded mass
vaccination campaigns operated by the YF initiative (WHO/UNICEF). YF vaccine is also used by Western travelers (YF-VAX,
Stamaril, Sanofi Pasteur) to endemic regions where certification is required for entry. Various militaries also use YF vaccine for troops
stationed in certain areas.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of Yellow Fever vaccination across endemic, travelers and military markets to 2030. The model contains value ($
m) and volume (mio doses) predictions/with supplier volume analysis. LO/BASE/HI forecast scenarios are included based upon
expected demand from further YF initiative activities (planned and unplanned). Safety considerations of current vaccines are
discussed along with new inactivated vaccines e.g. Xcellerex Inc are discussed along with other live-attenuated approaches e.g.
Crucell’s Flavimun.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 17.5%.
Please review the TERMS and CONDITIONS of purchase.
